BioSpace News Archive

Daxor Corporation announces a research letter in the Journal of the American College of Cardiology – Heart Failure reporting on the successful results of a pilot 31 patient randomized control trial conducted by the Duke Clinical Research Institute utilizing Daxor’s BVA-100 diagnostic to measure clinician assessment accuracy and the impact of optimizing decongestion therapy for heart failure patients with the diagnostic.

Ocean Biomedical, Inc. shared today an update on its broad range of promising programs in malaria, fibrosis, and multiple cancers.

Microbix Biosystems Inc. reports results for its third quarter and YTD fiscal 2023 ended June 30, 2023 (“ Q3 ” and “ YTD ”), a period in which strong revenues were realized along with a fully-funded partnering of its drug asset Kinlytic ® urokinase (“ Kinlytic ”).

ProPhase Labs, Inc., a next generation biotech, genomics, therapeutics and diagnostics company, reported its financial and operational results for the three months ended June 30, 2023.

On Target Laboratories, Inc. announced that the Centers for Medicare & Medicaid Services has granted a new technology add-on payment for CYTALUX for use in ovarian and lung cancer.

Lipocine Inc. today announced financial results for the second quarter and six months ended June 30, 2023, and provided a corporate update.

CymaBay Therapeutics, Inc. today announced the initiation of its 52-week, placebo-controlled, randomized, Phase 3 study.

Rhinostics has been selected to exhibit its RHINOstic® Automated Swab platform at the Vizient Innovative Technology Exchange.

AceLink Therapeutics, Inc. announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics, pharmacodynamics and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies.

Imperative Care, Inc., a medical technology company elevating care for people affected by stroke and other ischemic diseases, announced a new organizational structure designed to accelerate the company’s growth across its businesses.